DeepuMadduriMD

PubMed

• 2 citations
  Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
  Myo Htut, Binod Dhakal, Adam D Cohen, Thomas Martin, Jesus G Berdeja, Saad Z Usmani, Mounzer Agha, Carolyn C Jackson, Deepu Madduri, William Deraedt, Enrique Zudaire, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Dec 1
• 9 citations
  Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.
  Yi Lin, Noopur S Raje, Jesús G Berdeja, David S Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Monica Massaro, Fabio Pe...> ;Nature Medicine. 2023 Sep 1
• 2 citations
  Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.
  Thomas G Martin, Deepu Madduri, Lida Pacaud, Saad Z Usmani> ;Future Oncology. 2023 Nov 1
• Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.
  Jesus G Berdeja, Adam D Cohen, Thomas Martin, Deepu Madduri, Lida Pacaud, Sundar Jagannath> ;Future Oncology. 2023 Jun 1
• 4 citations
  Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the ...
  Adam D Cohen, Parameswaran Hari, Myo Htut, Jesus G Berdeja, Saad Z Usmani, Deepu Madduri, Yunsi Olyslager, Jenna D Goldberg, Jordan M Schecter, Carolyn C Jackson, Kath...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Jan 1
• 2 citations
  Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma.
  Thomas Martin, Carolyn C Jackson, Lida Pacaud, Deepu Madduri, Sundar Jagannath> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Jan 1
• 10 citations
  Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
  Thomas Martin, Yi Lin, Mounzer Agha, Adam D Cohen, Myo Htut, A Keith Stewart, Parameswaran Hari, Jesus G Berdeja, Saad Z Usmani, Tzu-Min Yeh, Yunsi Olyslager, Jenna D ...> ;The Lancet. Haematology. 2022 Dec 1
• 141 citations
  Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Fol...
  Thomas Martin, Saad Z Usmani, Jesus G Berdeja, Mounzer Agha, Adam D Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C Munshi...> ;Journal of Clinical Oncology. 2023 Feb 20
• 17 citations
  Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial.
  Gerard J Criner, Frederick M Lang, Robert L Gottlieb, Kusum S Mathews, Tisha S Wang, Todd W Rice, Deepu Madduri, Shashi Bellam, Robert Jeanfreau, Amy H Case, Marilyn K...> ;American Journal of Respiratory and Critical Care Medicine. 2022 Jun 1
• 8 citations
  A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma.
  Paula Restrepo, Sherry Bhalla, Yogita Ghodke-Puranik, Adolfo Aleman, Violetta Leshchenko, David T Melnekoff, Sarita Agte, Joy Jiang, Deepu Madduri, Joshua Richter, Sha...> ;JCO Precision Oncology. 2022 Jun 1
• 63 citations
  Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.
  Adam D Cohen, Samir Parekh, Bianca D Santomasso, Jaime Gállego Pérez-Larraya, Niels W C J van de Donk, Bertrand Arnulf, Maria-Victoria Mateos, Nikoletta Lendvai, Carol...> ;Blood Cancer Journal. 2022 Feb 24
• 77 citations
  Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.
  Oliver Van Oekelen, Adolfo Aleman, Bhaskar Upadhyaya, Sandra Schnakenberg, Deepu Madduri, Somali Gavane, Julie Teruya-Feldstein, John F Crary, Mary E Fowkes, Charles B...> ;Nature Medicine. 2021 Dec 1
• 28 citations
  Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications.
  Sherry Bhalla, David Melnekoff, Adolfo Aleman, Violetta V. Leshchenko, Paula Restrepo, Jonathan J Keats, Kenan Onel, Jeffrey R. Sawyer, Deepu Madduri, Joshua Richter, ...> ;Science Advances. 2021 Nov 19
• 1 citations
  Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma
  Tarek H. Mouhieddine, Julia Hieulle, Erin Moshier, Shambavi Richard, Joshua Richter, Hearn Jay Cho, Samir Parekh, Bart Barlogie, Ajai Chari, Sundar Jagannath, Deepu Ma...> ;Clinical Lymphoma Myeloma and Leukemia. 2021 Sep 11
• 37 citations
  Bispecific Antibodies in Multiple Myeloma: Present and Future.
  Guido Lancman, Dahniel Sastow, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Shambavi Richard, Joshua Richter, Larysa Sanchez, Ajai Chari> ;Blood Cancer Discovery. 2021 Aug 17
• 4 citations
  Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
  Ajai Chari, Erika Florendo, Ines Stefania Mancia, H.J. Cho, Deepu Madduri, Samir Parekh, Josh Richter, Amishi Dhadwal, Joanne Thomas, Grace Jiang, Alessandro Laganà, S...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Jul 18
• 534 citations
  Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CART...
  Jesus G. Berdeja, Deepu Madduri, Saad Z. Usmani, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, A. Keith Stewart, Parameswaran Hari, Myo Htut, Alexander M. Lesokhin,...> ;Lancet. 2021 Jul 24
• 1 citations
  Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma: Moving Into the Spotlight.
  Bo Wang, Sridevi Rajeeve, Deepu Madduri> ;Cancer Journal. 2021 May 1
• 7 citations
  Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
  Thomas G. Martin, Nina Shah, Joshua Richter, David H. Vesole, Sandy W. Wong, Chiung Yu Huang, Deepu Madduri, Sundar Jagannath, David S. Siegel, Noa Biran, Jeffrey L. W...> ;Cancer. 2021 Jun 1
• 863 citations
  Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
  Nikhil C. Munshi, Larry D Anderson, Nina Shah, Deepu Madduri, Jesus G. Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, David S. Siegel, A. Oriol, Philippe Moreau, Ibrahim ...> ;The New England Journal of Medicine. 2021 Feb 25
• 5 citations
  Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
  Deepu Madduri, Samir Parekh, Thomas B. Campbell, F. Neumann, Fabio Petrocca, Sundar Jagannath> ;Journal of Medical Case Reports. 2021 Feb 19
• 10 citations
  Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma
  Guido Lancman, Katleen S Lozada, Nida Athar, Samantha E. Jacobs, John Doucette, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Shambavi Richard, Joshua ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 May 1
• 18 citations
  Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
  Deepu Madduri, M Hagiwara, Kejal Parikh, Corey Pelletier, Thomas E. Delea, Arianna Kee, Ajai Chari> ;Future Oncology. 2021 Feb 1
• 21 citations
  B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
  Larysa Sanchez, Alexandra Dardac, Deepu Madduri, Shambavi Richard, Joshua Richter> ;Therapeutic Advances in Hematology. 2021 Jan 30
• 7 citations
  Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
  Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Shambavi Richard, Lowena Tam, Daniel Verina, Ajai Chari> ;Therapeutic Advances in Hematology. 2021 Jan 22
• Join now to see all

Journal Articles

• Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma  
  Nikhil C Munshi, Larry D Anderson, Deepu Madduri, Sagar Lonial, Noopur Raje, Fabio Petrocca, Kristen Hege, The New England Journal of Medicine

Abstracts/Posters

• Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
  Deepu Madduri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
  Deepu Madduri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R M...
  Deepu Madduri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes
  Deepu Madduri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma
  Deepu Madduri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance
  Deepu Madduri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018